437 related articles for article (PubMed ID: 14979734)
1. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
Lorenzo Sellares V; Torres Ramírez A
Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
[TBL] [Abstract][Full Text] [Related]
2. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Hyperphosphataemia: treatment options.
Malberti F
Drugs; 2013 May; 73(7):673-88. PubMed ID: 23625273
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of combination therapy for hyperphosphataemia with calcium-containing phosphate binders and sevelamer in hypercalcaemic haemodialysis patients.
McIntyre CW; Patel V; Taylor GS; Fluck RJ
Nephrol Dial Transplant; 2002 Sep; 17(9):1643-8. PubMed ID: 12198217
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sevelamer in the treatment of uncontrolled hyperphosphataemia of haemodialysis patients.
Almirall J; Lopez T; Vallve M; Ruiz A; Llibre J; Betriu A
Nephron Clin Pract; 2004; 97(1):c17-22. PubMed ID: 15153763
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
[TBL] [Abstract][Full Text] [Related]
8. Hyperphosphataemia and treatment with sevelamer in haemodialysis patients.
Cizman B
Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v47-9. PubMed ID: 12817070
[TBL] [Abstract][Full Text] [Related]
9. Hyperphosphataemia as a cardiovascular risk factor -- how to manage the problem.
Cannata-Andía JB; Rodríguez-García M
Nephrol Dial Transplant; 2002; 17 Suppl 11():16-9. PubMed ID: 12386251
[TBL] [Abstract][Full Text] [Related]
10. Calcium salts in the treatment of hyperphosphatemia in hemodialysis patients.
Nolan CR; Qunibi WY
Curr Opin Nephrol Hypertens; 2003 Jul; 12(4):373-9. PubMed ID: 12815333
[TBL] [Abstract][Full Text] [Related]
11. The safety of phosphate binders.
Almirall J; Valenzuela MP
Expert Opin Drug Saf; 2006 Sep; 5(5):675-86. PubMed ID: 16907657
[TBL] [Abstract][Full Text] [Related]
12. Safety of new phosphate binders for chronic renal failure.
Loghman-Adham M
Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
[TBL] [Abstract][Full Text] [Related]
13. Management of disturbances of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia.
Locatelli F; Cannata-Andía JB; Drüeke TB; Hörl WH; Fouque D; Heimburger O; Ritz E
Nephrol Dial Transplant; 2002 May; 17(5):723-31. PubMed ID: 11981055
[TBL] [Abstract][Full Text] [Related]
14. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
15. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients.
Gallieni M; Cozzolino M; Carpani P; Zoni U; Brancaccio D
J Nephrol; 2001; 14(3):176-83. PubMed ID: 11439741
[TBL] [Abstract][Full Text] [Related]
16. Long-term comparison of sevelamer hydrochloride to calcium-containing phosphate binders.
Brewster UC; Ciampi MA; Abu-Alfa AK; Reilly RF
Nephrology (Carlton); 2006 Apr; 11(2):142-6. PubMed ID: 16669977
[TBL] [Abstract][Full Text] [Related]
17. Intensive Hemodialysis, Mineral and Bone Disorder, and Phosphate Binder Use.
Copland M; Komenda P; Weinhandl ED; McCullough PA; Morfin JA
Am J Kidney Dis; 2016 Nov; 68(5S1):S24-S32. PubMed ID: 27772640
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost-efficiency of phosphate binders in hemodialysis.
Fröschl B; Brunner-Ziegler S; Hiebinger C; Wimmer A; Zsifkovits J
GMS Health Technol Assess; 2009 Jun; 5():Doc08. PubMed ID: 21289895
[TBL] [Abstract][Full Text] [Related]
19. [Renal osteodystrophy (3); its treatment in dialysis patients].
Ghitu S; Oprisiu R; Benamar L; Said S; Tataru Albu A; Arsenescu I; el Esper N; Morinière P; Fournier A
Nephrologie; 2000; 21(8):413-24. PubMed ID: 11213385
[TBL] [Abstract][Full Text] [Related]
20. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
